SouthState Corp’s Intellia Therapeutics NTLA Stock Holding History

SouthState Corp’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20	Closed	-$188	–	1513
2025 Q2	$188	Buy	+20	New	+$164	﹤0.01%	1545

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CGH

Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SouthState Corp's NTLA Position: Q3 2025 in Review

SouthState Corp sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 20 shares — an estimated $188 sold.

SouthState Corp first reported a position in NTLA in Q2 2025 and held it in 1 quarter. The position peaked at $188 in Q2 2025. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

SouthState Corp reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
SouthState Corp sold 20 Intellia Therapeutics shares in Q3 2025, an estimated $188.
SouthState Corp first reported a position in Intellia Therapeutics in Q2 2025 and held it in 1 quarter.
SouthState Corp's Intellia Therapeutics position peaked at $188 in Q2 2025.
282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on SouthState Corp's 13F filing for Q3 2025, filed 5 Nov 2025.